Eli Lilly Beats Q1 2026 Earnings Estimates, Raises Guidance
Eli Lilly (LLY) reported strong Q1 2026 results, beating analyst estimates. Revenue reached $12.5B, up 15% YoY, and EPS was $2.45. The company raised its full-year guidance, driven by strong sales of Mounjaro and Zepbound.
Key Numbers
Eli Lilly and Company (NYSE: LLY) reported first-quarter 2026 financial results that exceeded analyst expectations, driven by robust sales of its key drugs. Revenue came in at $12.5 billion, up 15% from the same quarter last year, while earnings per share (EPS) reached $2.45, beating the consensus estimate of $2.30. The stock rose 2% in after-hours trading.
Key Financial Results
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $12.5B | $10.9B | +15% |
| Net Income | $3.2B | $2.6B | +23% |
| EPS | $2.45 | $2.04 | +20% |
Highlights from the Release
The company attributed the strong performance to higher sales of diabetes drug Mounjaro and weight-loss drug Zepbound, which together generated $7.8 billion in revenue, up 25% year-over-year. Cancer drug Verzenio also contributed to the revenue growth.
Future Guidance
Eli Lilly raised its full-year 2026 guidance, now expecting revenue in the range of $50-$52 billion, compared to the prior forecast of $48-$50 billion. The company also lifted its EPS guidance to $10.50-$11.00.
Impact on Stock
Shares of LLY rose 2% in after-hours trading, reflecting investor optimism about the company's ability to sustain strong growth. Analysts point to continued strong demand for diabetes and obesity drugs as key drivers.
What This Means for Investors
Eli Lilly's results reinforce its leadership in the pharmaceutical sector, particularly in diabetes and obesity. With raised guidance, the company appears on a strong growth trajectory, but investors should monitor increasing competition and regulatory developments.
Frequently Asked Questions
Found this useful? Share it